NOUVELLES UTILISATIONS DE L'OMALIZUMAB

Swiss patent · CH720999 · Deleted

Register entry

Publication number
CH720999
Application number
CH000601/2024
Kind
Swiss patent
Status
Deleted
Specification
Application, without search report
Filed
Jun 4, 2024
Published
Feb 14, 2025
Deleted
Oct 9, 2026
Reason
Withdrawn
IPC classes
A61K 39/395 (2006.01)
A61P 11/02 (2006.01)
A61P 11/06 (2006.01)
A61P 17/04 (2006.01)
A61P 37/08 (2006.01)
CPC classes
A61K 39/39566 (2013-01-01)
A61P 11/02 (2018-01-01)
A61P 11/06 (2018-01-01)
A61P 17/04 (2018-01-01)
A61P 37/08 (2018-01-01)
Priority
EP EP23188544.3 28.07.2023
EP 24171754.5 22.04.2024
Specifications
14.02.2025 A2
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 9, 2026

    Withdrawn

    Status of protective title
    Active → Cancelled
    Cancellation date
    09.10.2026
    Cause for cancellation
    Application withdrawn

    Published in Swissreg on 09.10.2026

  2. Feb 14, 2025

    Specification status

    Specification status
    Non-published patent application → Patent application without search report
    Publication date
    14.02.2025

    Published in Swissreg on 14.02.2025

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

GENENTECH, INC.

Genentech, Inc.

1 DNA Way, South San Francisco,, California 94080-4990, US

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

Mathieu Paul-Léon Rigollet

68510 Uffheim, FR

Maria Chaikou

4056 Basel

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.